Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barr...
Leadership
Richard N. Kender B.S., M.B.A.
Interim CEO & Executive Chair
Matthew R. Henn Ph.D.
President & Chief Scientific Officer
Marella Thorell CPA
Executive VP, CFO & Treasurer
Thomas J. DesRosier Esq., J.D.
Executive VP, Chief Legal Officer & Secretary
Kelly Brady M.S.
Executive VP & COO
Chris McChalicher
Executive VP & CTO
Dennis M. Walling M.D.
Senior VP of Clinical Development & Head of Clinical Research
